Bristol Historical Income Statement

BMY Stock

USD 59.27 0.53 0.90%

Historical analysis of Bristol Myers income statement accounts such as Interest Expense of 1.2 B, Selling General Administrative of 3.6 B or Total Revenue of 47.3 B can show how well Bristol Myers Squibb performed in making a profits. Evaluating Bristol Myers income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bristol Myers's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Bristol Myers Squibb latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bristol Myers Squibb is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Bristol Income Statement Analysis

Bristol Myers Squibb Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bristol Myers shareholders. The income statement also shows Bristol investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Bristol Myers Income Statement Chart

At this time, Bristol Myers' Net Income Applicable To Common Shares is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 8.7 B in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Bristol Myers Squibb generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Bristol Myers Squibb minus its cost of goods sold. It is profit before Bristol Myers operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bristol Myers Squibb. It is also known as Bristol Myers overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Bristol Myers' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2021	2022	2023	2024 (projected)
Gross Profit	36.4B	36.0B	34.3B	36.0B
Total Revenue	46.4B	46.2B	45.0B	47.3B

Gross Profit Total Revenue

Bristol Myers income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling And Marketing Expenses	Minority Interest	Discontinued Operations	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.97	0.77	0.96	0.97	0.84	0.79	0.32	0.84	0.8	0.96	0.04	-0.97	0.16	-0.01	0.89	0.25	-0.28	-0.51	0.08	0.37	-0.08	0.01	-0.98	0.75	0.98
Interest Expense	0.97		0.79	0.97	0.96	0.88	0.75	0.27	0.8	0.86	0.94	-0.01	-0.94	0.11	0.04	0.93	0.33	-0.32	-0.45	0.04	0.44	-0.12	0.06	-1.0	0.68	0.97
Selling General Administrative	0.77	0.79		0.76	0.75	0.79	0.55	0.22	0.63	0.81	0.66	0.09	-0.78	0.07	0.08	0.67	0.22	-0.06	-0.13	0.1	-0.04	-0.01	0.0	-0.82	0.49	0.82
Total Revenue	0.96	0.97	0.76		1.0	0.84	0.85	0.45	0.89	0.85	0.97	0.17	-0.93	0.27	0.07	0.94	0.25	-0.24	-0.53	0.18	0.47	-0.16	0.07	-0.96	0.77	0.94
Gross Profit	0.97	0.96	0.75	1.0		0.83	0.85	0.48	0.91	0.83	0.96	0.21	-0.94	0.31	0.04	0.93	0.25	-0.24	-0.53	0.21	0.46	-0.18	0.04	-0.95	0.79	0.94
Other Operating Expenses	0.84	0.88	0.79	0.84	0.83		0.46	0.1	0.61	0.94	0.74	-0.03	-0.82	-0.09	0.24	0.88	0.63	-0.27	-0.01	-0.18	0.39	0.12	0.27	-0.87	0.4	0.9
Operating Income	0.79	0.75	0.55	0.85	0.85	0.46		0.72	0.93	0.56	0.88	0.44	-0.77	0.61	-0.14	0.68	-0.25	-0.09	-0.81	0.54	0.34	-0.42	-0.19	-0.74	0.92	0.71
Ebit	0.32	0.27	0.22	0.45	0.48	0.1	0.72		0.78	0.18	0.4	0.91	-0.37	0.95	-0.09	0.26	-0.26	0.03	-0.48	0.91	0.18	-0.57	-0.16	-0.26	0.67	0.24
Ebitda	0.84	0.8	0.63	0.89	0.91	0.61	0.93	0.78		0.63	0.86	0.54	-0.85	0.65	-0.06	0.74	0.02	-0.17	-0.61	0.57	0.35	-0.38	-0.09	-0.79	0.87	0.79
Cost Of Revenue	0.8	0.86	0.81	0.85	0.83	0.94	0.56	0.18	0.63		0.76	0.06	-0.77	-0.03	0.28	0.86	0.45	-0.21	-0.11	-0.09	0.4	0.04	0.29	-0.85	0.46	0.86
Total Operating Expenses	0.96	0.94	0.66	0.97	0.96	0.74	0.88	0.4	0.86	0.76		0.09	-0.91	0.26	-0.04	0.91	0.11	-0.32	-0.67	0.16	0.5	-0.18	-0.02	-0.93	0.83	0.92
Income Before Tax	0.04	-0.01	0.09	0.17	0.21	-0.03	0.44	0.91	0.54	0.06	0.09		-0.1	0.9	-0.01	0.01	-0.23	0.12	-0.15	0.88	0.02	-0.48	-0.11	0.02	0.41	0.01
Total Other Income Expense Net	-0.97	-0.94	-0.78	-0.93	-0.94	-0.82	-0.77	-0.37	-0.85	-0.77	-0.91	-0.1		-0.23	0.12	-0.82	-0.27	0.22	0.44	-0.16	-0.32	0.2	0.1	0.95	-0.76	-0.96
Net Income	0.16	0.11	0.07	0.27	0.31	-0.09	0.61	0.95	0.65	-0.03	0.26	0.9	-0.23		-0.32	0.08	-0.34	-0.02	-0.47	0.96	0.16	-0.66	-0.37	-0.09	0.61	0.09
Income Tax Expense	-0.01	0.04	0.08	0.07	0.04	0.24	-0.14	-0.09	-0.06	0.28	-0.04	-0.01	0.12	-0.32		0.2	0.22	0.01	0.26	-0.33	-0.06	0.55	0.93	-0.04	-0.21	0.02
Research Development	0.89	0.93	0.67	0.94	0.93	0.88	0.68	0.26	0.74	0.86	0.91	0.01	-0.82	0.08	0.2		0.41	-0.38	-0.41	-0.05	0.6	0.01	0.25	-0.9	0.62	0.88
Selling And Marketing Expenses	0.25	0.33	0.22	0.25	0.25	0.63	-0.25	-0.26	0.02	0.45	0.11	-0.23	-0.27	-0.34	0.22	0.41		-0.41	0.53	-0.44	0.44	0.27	0.4	-0.31	-0.2	0.32
Minority Interest	-0.28	-0.32	-0.06	-0.24	-0.24	-0.27	-0.09	0.03	-0.17	-0.21	-0.32	0.12	0.22	-0.02	0.01	-0.38	-0.41		0.16	0.05	-0.67	0.02	-0.25	0.32	-0.25	-0.29
Discontinued Operations	-0.51	-0.45	-0.13	-0.53	-0.53	-0.01	-0.81	-0.48	-0.61	-0.11	-0.67	-0.15	0.44	-0.47	0.26	-0.41	0.53	0.16		-0.43	-0.32	0.4	0.28	0.44	-0.78	-0.37
Net Income From Continuing Ops	0.08	0.04	0.1	0.18	0.21	-0.18	0.54	0.91	0.57	-0.09	0.16	0.88	-0.16	0.96	-0.33	-0.05	-0.44	0.05	-0.43		-0.01	-0.69	-0.4	-0.04	0.54	0.01
Non Recurring	0.37	0.44	-0.04	0.47	0.46	0.39	0.34	0.18	0.35	0.4	0.5	0.02	-0.32	0.16	-0.06	0.6	0.44	-0.67	-0.32	-0.01		-0.22	0.18	-0.38	0.37	0.34
Non Operating Income Net Other	-0.08	-0.12	-0.01	-0.16	-0.18	0.12	-0.42	-0.57	-0.38	0.04	-0.18	-0.48	0.2	-0.66	0.55	0.01	0.27	0.02	0.4	-0.69	-0.22		0.54	0.09	-0.51	-0.03
Tax Provision	0.01	0.06	0.0	0.07	0.04	0.27	-0.19	-0.16	-0.09	0.29	-0.02	-0.11	0.1	-0.37	0.93	0.25	0.4	-0.25	0.28	-0.4	0.18	0.54		-0.06	-0.22	0.04
Net Interest Income	-0.98	-1.0	-0.82	-0.96	-0.95	-0.87	-0.74	-0.26	-0.79	-0.85	-0.93	0.02	0.95	-0.09	-0.04	-0.9	-0.31	0.32	0.44	-0.04	-0.38	0.09	-0.06		-0.67	-0.97
Interest Income	0.75	0.68	0.49	0.77	0.79	0.4	0.92	0.67	0.87	0.46	0.83	0.41	-0.76	0.61	-0.21	0.62	-0.2	-0.25	-0.78	0.54	0.37	-0.51	-0.22	-0.67		0.67
Reconciled Depreciation	0.98	0.97	0.82	0.94	0.94	0.9	0.71	0.24	0.79	0.86	0.92	0.01	-0.96	0.09	0.02	0.88	0.32	-0.29	-0.37	0.01	0.34	-0.03	0.04	-0.97	0.67

Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.1B	10.5B	10.8B	10.3B	9.8B	10.3B
Interest Expense	656M	1.4B	1.3B	1.2B	1.2B	1.2B
Selling General Administrative	4.9B	7.7B	7.7B	7.8B	6.4B	3.6B
Total Revenue	26.1B	42.5B	46.4B	46.2B	45.0B	47.3B
Gross Profit	18.1B	30.7B	36.4B	36.0B	34.3B	36.0B
Other Operating Expenses	20.2B	40.3B	37.8B	37.1B	28.4B	16.9B
Operating Income	5.5B	5.1B	10.2B	10.3B	16.6B	17.4B
Ebit	5.5B	(5.5B)	9.4B	8.9B	9.6B	10.1B
Ebitda	6.6B	5.0B	20.2B	19.2B	19.4B	20.4B
Cost Of Revenue	8.1B	11.8B	9.9B	10.1B	10.7B	5.8B
Total Operating Expenses	12.2B	28.6B	27.9B	26.9B	34.3B	36.0B
Income Before Tax	5.0B	(6.9B)	8.1B	7.7B	8.4B	4.2B
Total Other Income Expense Net	(489M)	(7.4B)	(9.3B)	(10.6B)	(8.2B)	(7.8B)
Net Income	3.4B	(9.0B)	7.0B	6.3B	8.0B	8.4B
Income Tax Expense	1.5B	2.1B	1.1B	1.4B	400M	380M
Research Development	6.1B	11.1B	10.2B	9.5B	9.3B	9.8B
Selling And Marketing Expenses	4.9B	7.7B	7.7B	7.8B	1.4B	1.3B
Net Income Applicable To Common Shares	3.4B	(9.0B)	7.0B	6.3B	5.7B	6.0B
Minority Interest	21M	20M	(20M)	(18M)	(16.2M)	(15.4M)
Net Income From Continuing Ops	6.5B	(9.0B)	7.0B	6.3B	8.3B	8.7B
Non Operating Income Net Other	(938M)	2.3B	720M	(576M)	(662.4M)	(629.3M)
Tax Provision	1.5B	2.1B	1.1B	1.4B	322M	305.9M
Net Interest Income	(656M)	(1.4B)	(1.3B)	(1.2B)	(1.1B)	(1.2B)
Interest Income	69M	71M	550M	1.9B	2.1B	2.2B
Reconciled Depreciation	1.7B	10.4B	10.0B	9.6B	9.8B	6.8B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Historical Income Statement

About Bristol Income Statement Analysis

Bristol Myers Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Bristol Myers income statement Correlations

Bristol Myers Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bristol Myers income statement Accounts

Also Currently Popular

Additional Tools for Bristol Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Reconciled Depreciation	+ 0.98	Depreciation And Amortization
Interest Expense	+ 0.97	Depreciation And Amortization
Gross Profit	+ 0.97	Depreciation And Amortization
Total Revenue	+ 0.97	Interest Expense
Reconciled Depreciation	+ 0.97	Interest Expense

Net Interest Income	- 1.0	Interest Expense
Net Interest Income	- 0.98	Depreciation And Amortization
Reconciled Depreciation	- 0.97	Net Interest Income
Total Other Income Expense Net	- 0.97	Depreciation And Amortization
Reconciled Depreciation	- 0.96	Total Other Income Expense Net
Net Interest Income	- 0.96	Total Revenue